Akari Therapeutics plc has unveiled a new pipeline candidate, AKTX-102, an antibody-drug conjugate (ADC) directed against CEACAM5, a novel target highly relevant in gastrointestinal and lung cancers.
Starkage Therapeutics SAS has established a research collaboration with Gustave Roussy to characterize cellular senescence induced by standard-of-care treatments in a series of digestive cancers.
Shionogi & Co. Ltd. and Fosun Pharmaceutical (Group) Co. Ltd. were involved in separate divestment transactions this week, with Shionogi buying out Pfizer Inc.’s stake in Viiv Healthcare Ltd. to lift its holding to 21.7%.
